^
Association details:
| Biomarker: | BRCA1 expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) + albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
Excerpt:
The GOG-172 was a phase III, multi-institutional randomised trial of intravenous paclitaxel and cisplatin (IV therapy) vs intravenous paclitaxel, intraperitoneal cisplatin plus paclitaxel (IP therapy) in patients with optimally resected stage III EOC. The BRCA1 expression was assessed...In tumours with aberrant BRCA1 expression, the median OS was 84 vs 47 months in the IP vs IV group, respectively (P=0.0002).
DOI:
https://doi.org/10.1038/bjc.2013.70
